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Several monosaccharide esters were recently introduced as new tools in biomedical research. [1] . These esters seem to be able to cross the plasma membrane without requiring the intervention of a specific carrier system. They then undergo intracellular hydrolysis in esterase-catalysed reactions, so that their glucidic moiety becomes readily available for further metabolism or metabolic action [2, 3] . The major aim of this brief review is to draw attention to the possible use of some of these esters as new insulinotropic tools in the treatment of such diseases as Type II (non-insulin-dependent) diabetes mellitus, insulinoma or persistent hyperinsulinaemia in childhood. In the treatment of diabetes, they could be used in combination with other insulinotropic agents such as hypoglycaemic sulphonylureas [ 
Experimental findings
Esters of metabolized hexoses, such as a-d-glucose pentaacetate or b-d-glucose pentaacetate, stimulate insulin release from islets incubated either in the absence of any exogenous nutrient or in the presence of such nutrient secretagogues as d-glucose and l-leucine [47] or, as shown in Figure 1 , the dimethyl ester of succinic acid (SAD). Unexpectedly, however, some esters of non-metabolized hexoses, such as a-l-glucose pentaacetate and b-l-glucose pentaacetate also show positive insulinotropic action, the most obvious effect being in islets exposed to another nutrient secretagogue, e. g. l-leucine or the dimethyl ester of succinic acid (Fig. 1) . Even more surprisingly, monosaccharide esters that inhibit d-glucose metabolism (such as d-mannoheptulose hexaacetate or 2-deoxy-d-glucose tetraacetate) and suppress d-glucose-stimulated insulin release [48, 49] , were found to enhance the beta cell secretory response to non-glucidic nutrients, e. g. the dimethyl ester of succinic acid (Fig. 1) . When tested in suitably low concentrations, the tetraacetate esters of 2-deoxy-d-glucose even enhance insulin release stimulated by d-glucose [49] .
Detailed investigations on the metabolic fate of bl-glucose pentaacetate in isolated pancreatic islets and its effects on variables such as protein biosynthesis, cyclic AMP formation, generation of inositol phosphates, intracellular pH, 86 Rb efflux and bioelectrical activity, 45 Ca net uptake and efflux, cytosolic Ca 2+ concentration and insulin release suggest that the esters of non-metabolized monosaccharides with positive insulinotropic action may directly interact with a receptor system, resulting in a decrease in K + conductance, plasma membrane depolarization and induction of electrical activity [50] . This model is thought to have analogies with the recognition of bitter compounds by taste buds [51] . Purified islet beta cells indeed contain the a-gustducin G-protein involved in this recognition process (unpublished observation).
The findings mentioned above also raise the idea that some monosaccharide esters, especially those of l-glucose, can be used as insulinotropic tools to stimulate insulin release in Type II diabetes. They are indeed likely to bypass those site-specific defects in dglucose transport, phosphorylation and further metabolism currently held responsible for a preferential alteration of the diseased beta cell response to d-glucose in Type II diabetes [52] .
In light of such a proposal, the effects of several monosaccharide esters upon insulin secretion were compared in islets from either control rats or hereditarily diabetic Goto-Kakizaki rats (GK rats).
As illustrated in Figure 2 (upper panel), the rate of insulin release evoked by either 8.3 mmol/l d-glucose or 10.0 mmol/l l-leucine is much lower (p < 0.001) in islets from GK rats than in islets from control animals [53] . Relative to such a secretory rate, the enhancing action of 2-deoxy-d-glucose tetraacetate (1.7 mmol/l) upon glucose-stimulated insulin output and that of a-d-glucose pentaacetate (also 1.7 mmol/l) upon leucine-induced insulin release was more pronounced (p < 0.025 or less) in the diabetic animals than in the control rats (Fig. 2B) . Likewise, in islets exposed to the dimethyl ester of succinic acid, the absolute value for insulin release is lower (p < 0.001) in GK rats than in control animals (Fig. 3A) , but the relative magnitude of the enhancing action of either d-mannoheptulose hexaacetate or b-d-glucose pentaacetate (both 1.7 mmol/l) is higher (p < 0.02 or less) in GK rats than control animals (Fig. 3B) .
Relative to the paired reference value recorded in the presence of the dimethyl ester of succinic acid (10.0 mmol/l) alone, the output of insulin found in islets exposed to both the succinic acid ester and a-lglucose pentaacetate (1.7 mmol/l) was again higher in GK rats than in control animals, although such a difference failed to achieve statistical significance (p < 0.11). For b-l-glucose pentaacetate (also 1.7 mmol/l), the relative magnitude of enhancing action of the ester upon insulin release evoked by the dimethyl ester of succinic acid was even lower (p < 0.001) in GK rats than in control animals. In fact, the b-anomer of l-glucose pentaacetate failed to enhance significantly (p < 0.3) insulin output.
Inactivation of glycogen phosphorylase a by glucose could explain these findings [54] . It was indeed previously documented (i) that glycogen accumulates in the beta cell in situations of long-term hyperglycaemia , and (vii) that, probably as a result, the anomeric specificity of the beta cell secretory response to d-glucose is disturbed in Type II diabetic subjects [61] and in animal models of Type II diabetes [62±65], the normal preference for a-d-glucose being attenuated, suppressed or even reversed as a function of the severity and duration of the hyperglycaemic state [66] . Because the conformation of b-l-glucopyranose resembles that of a-d-glucopyranose at the level of the C 1 hemiacetal group [67] , the more pronounced insulinotropic action of a-l-glucose pentaacetate (as compared with b-l-glucose pentaacetate) in islets from GK rats might thus reflect the greater inactivation of glycogen phosphorylase a by the l-glucose b-anomer, which is produced by hydrolysis of its pentaacetate ester in the islet cells.
In conclusion, a-l-glucose pentaacetate can, therefore, be proposed as a novel insulinotropic tool in the treatment of Type II diabetes. This ester would offer the advantages of (i) bypassing the site-specific defects in d-glucose handling in the beta cell of diabetic patients, (ii) minimizing the inhibition of glycogenolysis otherwise attributable to interaction of b-l-glucose with phosphorylase a in the beta cell, and (iii) avoiding the stimulation of hepatic gluconeogenesis that may result from treatment with insulinotropic esters such as succinic acid dimethyl ester or d-glucose pentaacetate [68, 69] . This proposal is consistent with the recent observation that when normal rats were injected intravenously with no more pentaacetate ester of l-glucose than 8.8 nmol/g body weight, a sizeable increase in plasma insulin concentration was provoked within 2 min [70] .
Note that the stimulation of insulin release by the polyacetate esters of monosaccharides cannot be attributed to the catabolism of their acetate moiety. Indeed, some esters that are as efficiently taken up and hydrolysed in pancreatic islets as a-d-glucose pentaacetate or b-l-glucose pentaacetate, e. g. b-d-galactose pentaacetate, have no positive insulinotropic action [47, 71] .
Some of these esters may even inhibit nutrientstimulated insulin release [72, 73] . This is illustrated in Figure 4 , which indicates that a-d-galactose pentaacetate inhibits insulin release evoked by either lleucine or the dimethyl ester of succinic acid, whilst b-d-galactose pentaacetate inhibits less strongly ± or even fails to noticeably affect ± the secretory response to the non-glucidic nutrients. The pentaacetate ester of a-d-galactose (1.7 mmol/l) also inhibits d-glucose-stimulated insulin release [78] . The findings summarized in Figure 4 suggest that the receptor system mediating the beta cell functional response to the esters of non-metabolized or poorly metabolized monosaccharides could convey either a positive or negative message to the insulin-releasing effector machinery. These findings also led us to propose that the a-anomer of d-galactose pentaacetate could conceivably be used to prevent excessive insulin release in conditions such as persistent hyperinsulinaemia in childhood or insulinoma [72, 73] .
The possible use of monosaccharide esters as insulinotropic agents is supported by recent findings documenting their insulinotropic action after intravenous injection into anaesthetized rats [70, 74, 75] . Monosaccharide esters may also be used to potentiate the beta cell secretory response to agents such as gliquidone or repaglinide [74] . They seem to have no undesirable side effects and have been used safely in human subjects (unpublished observation). New modalities for giving them orally might be required, however, to achieve a stimulation of insulin release comparable with that found after intravenous injection [74] .
Concluding remark
Recent studies have shown that monosaccharide esters represent new tools to interfere specifically with a given biochemical reaction in intact cells [76, 77] or for antitumoural therapy [78±81]. The information briefly reviewed here indicates that the introduction of these esters also allows the detection of a novel modality for (in)activation of the pancreatic islet beta cells and might lead, therefore, to the development of new agents for the treatment of hypoinsulinaemic or hyperinsulinaemic diseases. 
